Phase III Studies and Guideline Recommendations*
* In Hong Kong, TS-ONE ® is indicated for post operative adjuvant chemotherapy for locally advanced (stage II (excluding T1), IIIA or IIIB) gastric cancer
Biliary Tract Cancer
- Vogel A. et al., 2023. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology 2023 Feb; 34(2), pp. 127-140.
- Shindo Y. et al., 2023. Clinical outcomes of second line chemotherapy after gemcitabine and cisplatin plus S 1 treatment for patients with advanced biliary tract cancer in the KHBO1401 3A study. Oncol Rep. 2023 Feb;49(2), pp. 41.
- Nakachi K. et al., 2023. Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2023 Jan 401(10372), pp. 195-203.
- Ioka T. et al., 2023. Kansai Hepatobiliary Oncology Group (KHBO). Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA). J Hepatobiliary Pancreat Sci. 2023 Jan; 30(1), pp. 102-110.
- Morizane C. et al., 2019. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/ recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
Ann Oncol., 30(12), pp.1950-1958. - Clinical practice guidelines for the management of biliary tract cancer 2015: the 2nd English edition.
This Site is intended for Hong Kong healthcare professionals only. Products discussed herein may have different labeling in different countries. TS-ONE® is a registered trademark of TAIHO PHARMACEUTICAL CO., LTD. and used under license. Copyright © TAIHO PHARMACEUTICAL CO., LTD. 2020 All rights reserved.